LTR Pharma has been named among the top performing IPOs on the Australian market this year in an article by business reporter Eli Greenblat in The Australian newspaper this week.
Reflecting on the sluggish market for new listings globally, he wrote:
“Among the best performers among the IPOs was LTR Pharma, which is working on the clinical development and commercialisation of an intranasal spray treatment for erectile dysfunction. Its shares are up 70 per cent from its float offer price.”